<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091141</url>
  </required_header>
  <id_info>
    <org_study_id>ML28897</org_study_id>
    <secondary_id>PRO 02</secondary_id>
    <nct_id>NCT02091141</nct_id>
  </id_info>
  <brief_title>My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors</brief_title>
  <official_title>My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of&#xD;
      six treatment regimens in participants with advanced solid tumors for whom therapies that&#xD;
      will convey clinical benefit are not available and/or are not suitable options per the&#xD;
      treating physician's judgment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 14, 2014</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1 for all arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1 for all arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Alive at Year 1</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1 for all arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atezolizumab-Treated Participants with tTMB ≥10 Mutations/Mb and &lt;16 Mutations/Mb With Overall Response, as Assessed by the Investigator</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atezolizumab-Treated Participants with Blood Tumor Mutational Burden (bTMB) ≥16 Mutations With Overall Response, as Assessed by the IRC</measure>
    <time_frame>From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Tumor response will be assessed using RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>Neoplasms</condition>
  <condition>Solid Tumors</condition>
  <condition>Biliary Cancer</condition>
  <condition>Salivary Cancer</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab Plus Pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vemurafenib Plus Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive alectinib 600 mg orally BID in each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Trastuzumab Plus Pertuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Trastuzumab Plus Pertuzumab</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Vemurafenib Plus Cobimetinib</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Vemurafenib Plus Cobimetinib</arm_group_label>
    <other_name>Cotellic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Vismodegib</arm_group_label>
    <other_name>Erivedge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Alectinib</arm_group_label>
    <other_name>Alecensa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy greater than or equal to (≥) 12 weeks&#xD;
&#xD;
          -  Histologically documented metastatic cancer (solid tumors, not including hematologic&#xD;
             malignancies)&#xD;
&#xD;
          -  Participants who have received standard first-line therapy for metastatic cancer&#xD;
             (except for the tumors for which no first-line therapy exists) and in whom a trial of&#xD;
             targeted therapy is considered the best available treatment option. Eligible&#xD;
             participants should not have available therapies that will convey clinical benefit&#xD;
             and/or are not suitable options per the treating physician's judgment&#xD;
&#xD;
          -  No previous treatment with the specific assigned study drug or any other drug sharing&#xD;
             the same target&#xD;
&#xD;
          -  Measurable disease by RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 (For&#xD;
             patients enrolling in the atezolizumab arm, ECOG score must be documented within 7&#xD;
             days prior to first treatment and confirmation of ECOG PS must be entered into the&#xD;
             interactive web response system [IWRS] prior to initiation of treatment)&#xD;
&#xD;
          -  Adequate hematologic, renal, and liver function as defined by the protocol&#xD;
&#xD;
          -  If applicable, use of contraception methods or abstinence as defined by the protocol&#xD;
&#xD;
        Study-Drug Specific Inclusion Criteria:&#xD;
&#xD;
        Trastuzumab plus Pertuzumab&#xD;
&#xD;
          -  Molecular testing results from clinical laboratory improvement amendments&#xD;
             (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2&#xD;
             overexpression or amplification. Participants must have one of the following tumor&#xD;
             types: biliary cancer, salivary cancer, or bladder cancer&#xD;
&#xD;
             a) For participants screened using a blood assay: obtain tissue-based testing result&#xD;
             confirming study eligibility (within first 4 weeks after enrollment)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) greater than (&gt;) 50 percent (%) or above the&#xD;
             lower limit of the institutional normal range, whichever is lower&#xD;
&#xD;
          -  Availability of an archival or new pre-treatment tissue sample is required if&#xD;
             molecular testing was not performed by Foundation Medicine. Any available tumor tissue&#xD;
             sample can be submitted. The tissue sample must be submitted within 4 weeks after&#xD;
             enrollment&#xD;
&#xD;
        Erlotinib&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories (using tissue and/or blood)&#xD;
             demonstrating EGFR-activating mutations&#xD;
&#xD;
        Vemurafenib plus Cobimetinib&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories (using tissue and/or blood)&#xD;
             demonstrating BRAF V600 mutations a) For participants screened using a blood assay:&#xD;
             obtain tissue-based testing result confirming study eligibility (within first 4 weeks&#xD;
             after enrollment)&#xD;
&#xD;
        Vismodegib&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories (using tissue and/or blood)&#xD;
             demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened&#xD;
             [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1])&#xD;
&#xD;
             a) For participants screened using a blood assay: obtain tissue-based testing result&#xD;
             confirming study eligibility (within first 4 weeks after enrollment)&#xD;
&#xD;
          -  All non-hematological adverse events related to any prior chemotherapy, surgery, or&#xD;
             radiotherapy must have resolved to National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (≤) 2 prior to&#xD;
             starting therapy&#xD;
&#xD;
        Alectinib&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories (using tissue and/or blood)&#xD;
             demonstrating anaplastic lymphoma kinase (ALK) gene rearrangements, ALK mutations, ALK&#xD;
             copy number gain or (for melanoma only) increased ALK expression or presence of&#xD;
             ALK-alternative transcription initiation transcript (ALKATI) a) For participants&#xD;
             screened using a blood assay: obtain tissue-based testing result confirming study&#xD;
             eligibility (within first 4 weeks after enrollment)&#xD;
&#xD;
        Atezolizumab&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories (using tissue)&#xD;
             demonstrating elevated tissue tumor mutational burden (tTMB ≥10 mutations/ Megabase&#xD;
             [Mb])&#xD;
&#xD;
          -  For patients where molecular testing was not performed using Foundation Medicine,&#xD;
             submission of an archival or new pretreatment tissue sample is mandatory. For patients&#xD;
             where molecular testing was performed using Foundation Medicine, submission of an&#xD;
             archival or new pretreatment tissue sample is required, if available. The tissue&#xD;
             sample must be submitted within 4 weeks after enrollment&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Participants with hematologic malignancies&#xD;
&#xD;
          -  Concurrent administration of any other anti-cancer therapy (except male participants&#xD;
             with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are&#xD;
             allowed; Most recent anti-cancer therapy ≤28 days and have not recovered from the side&#xD;
             effects, excluding alopecia; Radiation therapy within ≤14 days&#xD;
&#xD;
          -  Active or untreated brain metastases&#xD;
&#xD;
          -  History of carcinomatous meningitis&#xD;
&#xD;
          -  Uncontrolled concurrent malignancy (early stage is allowed if not requiring active&#xD;
             therapy or intervention)&#xD;
&#xD;
          -  Pregnant or breastfeeding women, or intending to become pregnant during the study&#xD;
&#xD;
          -  Any significant cardiovascular events within 6 months prior to study entry&#xD;
&#xD;
          -  Pulmonary embolism within 30 days prior to study entry&#xD;
&#xD;
          -  History or presence of clinically significant ventricular or atrial dysrhythmia &gt;Grade&#xD;
             2 per NCI CTCAE v4.0&#xD;
&#xD;
          -  Any other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol&#xD;
&#xD;
        Study-Drug Specific Exclusion Criteria:&#xD;
&#xD;
        Trastuzumab plus Pertuzumab&#xD;
&#xD;
          -  Previous treatment with any HER2-targeted therapy&#xD;
&#xD;
        Erlotinib&#xD;
&#xD;
          -  Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19&#xD;
             deletions or exon 21 L858R substitution mutations&#xD;
&#xD;
          -  EGFR amplifications in the absence of EGFR-activating mutations&#xD;
&#xD;
          -  Cancers with exon 20 mutations&#xD;
&#xD;
          -  Previous treatment with erlotinib or any other EGFR inhibitor&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude absorption of erlotinib&#xD;
&#xD;
        Vemurafenib plus Cobimetinib&#xD;
&#xD;
          -  Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic&#xD;
             malignancy including multiple myeloma&#xD;
&#xD;
          -  LVEF below institutional lower level of normal (LLN) or below 50%, whichever is lower&#xD;
&#xD;
          -  History of or evidence of retinal pathology on ophthalmologic examination that is&#xD;
             considered a risk factor for neurosensory retinal detachment, retinal vein occlusion&#xD;
             (RVO), or neovascular macular degeneration&#xD;
&#xD;
          -  Presence of any of the following conditions, which are risk factors for RVO:&#xD;
             Uncontrolled glaucoma with intraocular pressure &gt;21 millimetres of mercury (mm Hg);&#xD;
             Serum cholesterol ≥Grade 2; Hypertriglyceridemia ≥Grade 2; Hyperglycemia (fasting)&#xD;
             ≥Grade 2; Grade ≥2 uncontrolled hypertension (participants with a history of&#xD;
             hypertension controlled with anti-hypertensive medication to Grade &lt;/=1 are eligible)&#xD;
&#xD;
          -  Prior or concurrent malignancy with known RAS mutation&#xD;
&#xD;
          -  Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is&#xD;
             allowed)&#xD;
&#xD;
          -  Previous treatment with cobimetinib or any other mitogen-activated&#xD;
             protein/extracellular signal-regulated kinase (MEK) inhibitor&#xD;
&#xD;
          -  Prior treatment with a RAF inhibitor&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude absorption of vemurafenib&#xD;
&#xD;
          -  History of congenital long QT syndrome or mean (average of triplicate measurements)&#xD;
             corrected QT (QTc) measured using Fridericia's method ≥450 millisecond (ms) at&#xD;
             baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium,&#xD;
             calcium, magnesium, phosphorus)&#xD;
&#xD;
        Vismodegib&#xD;
&#xD;
          -  Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or&#xD;
             hematologic malignancies&#xD;
&#xD;
          -  Previous treatment with vismodegib or any other hedgehog pathway inhibitor&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude absorption of vismodegib&#xD;
&#xD;
        Alectinib&#xD;
&#xD;
          -  ALK-positive NSCLC, neuroblastoma, and childhood tumors&#xD;
&#xD;
          -  Previous treatment with alectinib or any other ALK inhibitor&#xD;
&#xD;
          -  Participants with symptomatic bradycardia&#xD;
&#xD;
          -  Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within&#xD;
             14 days prior to the first dose of study treatment and while on treatment with&#xD;
             alectinib&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude absorption of alectinib&#xD;
&#xD;
        Atezolizumab&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled tumor pain&#xD;
&#xD;
          -  Asymptomatic metastatic lesions that would likely cause functional deficits or&#xD;
             intractable pain with further growth (e.g., epidural metastasis that is not currently&#xD;
             associated with spinal cord compression) should be considered for loco-regional&#xD;
             therapy if appropriate prior to enrollment&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently). Patients with indwelling&#xD;
             catheters are allowed&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1&#xD;
             inhibitor&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary&#xD;
             cells&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the atezolizumab formulation&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV)&#xD;
             infection, active hepatitis C virus (HCV) infection or active tuberculosis&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to initiation of study treatment, unstable arrhythmia, or unstable angina&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis within 4 weeks prior to initiation&#xD;
             of study treatment, or anticipation of need for a major surgical procedure during the&#xD;
             course of the study&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment, or anticipation of need for such a vaccine during the course of the study&#xD;
             or within 5 months after the final dose of atezolizumab&#xD;
&#xD;
          -  History of other malignancy within 5 years prior to screening, with the exception of&#xD;
             those with a negligible risk of metastasis or death, such as adequately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate&#xD;
             cancer, ductal carcinoma in situ, or Stage I uterine cancer&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the participant at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune&#xD;
             checkpoint blockade therapies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of&#xD;
             the drug (whichever is longer) prior to randomization&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication within 2 weeks prior to&#xD;
             initiation of study treatment, or anticipation of need for systemic immunosuppressive&#xD;
             medication during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Regional Medical Center at Cancer Treatment Centers of America</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Science 37, Inc</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center; Dept Clinical Trials Office</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Florida Cancer Specialists South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist, North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists, Research Department</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC; Research</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center; Oncology Research Dept-5C</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago Medical Center; Section Of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Med Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center - Antibiotic Research Associates, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering - Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Univ Medical Ctr; Breast Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ No Carolina School of Med; Physicians Office Bldg</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305v</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Univ Health Svcs; Internal Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Regional Medical Ctr</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Cnt Onco Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Onc., PLLC - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

